The prescriptions drug market is changing. The disparity of prescription drug prices among countries, along withrna growing concern about the availability of affordable medicine, has catalyzed the sale of lower-priced drugs outside the authorized distribution channels of branded drug companies. These gray market goods, also known as parallel imports, are goods produced under intellectual property rights held by the owner (or its licensee) for legitimate sale in one market that are then diverted and distributed in a second market without the authorization of the intellectual property rights owner.
展开▼
